• 文献标题:   Concise nanotherapeutic modality for cancer involving graphene oxide dots in conjunction with ascorbic acid
  • 文献类型:   Article
  • 作  者:   SHIH CY, WANG PT, CHUNG WP, WANG WH, CHIANG IT, SU WC, HUANG WL, TENG HS
  • 作者关键词:  
  • 出版物名称:   NANOSCALE
  • ISSN:   2040-3364 EI 2040-3372
  • 通讯作者地址:  
  • 被引频次:   0
  • DOI:   10.1039/d3nr00431g EA APR 2023
  • 出版年:   2023

▎ 摘  要

Cancer cells tend to have higher intracellular reactive oxygen species (ROS) levels and are more vulnerable to ROS-generating therapies such as ascorbic acid (H(2)Asc) therapy, whose potency has been explored by several clinical trials. However, its efficiency is restricted by the requirement of pharmacologically high local H(2)Asc concentrations. Here, we show that nitrogen-doped graphene oxide dots (NGODs), which are highly crystalline and biocompatible, can serve as a catalytic medium for improving H(2)Asc cancer therapy at orally achievable physiological H(2)Asc concentrations. NGODs catalyze H(2)Asc oxidation for H2O2 and dehydroascorbic acid generation to disrupt cancer cells by consuming intracellular glutathione (GSH) and inducing ROS damage. This is the first study to demonstrate the direct consumption of GSH using a carbon-based nano-catalyst (NGODs), which further expedites tumor killing. In addition, as in our previous study, NGODs can also serve as a highly efficient photosensitizer for photodynamic therapy. Under illumination, NGODs produce a considerable amount of H2O2 in the presence of physiological levels of H(2)Asc as a hole scavenger and further enhance the therapeutic efficiency. Thus, a concise nanotherapeutic modality could be achieved through the conjunction of multifunctional NGODs and H(2)Asc to selectively eliminate deep-seated and superficial tumors simultaneously (under 65% of normal cell viability, it kills almost all cancer cells). Note that this level of therapeutic versatility generally requires multiple components and complex manufacturing processes that run into difficulties with FDA regulations and clinical applications. In this study, the concise NGOD-H(2)Asc nanotherapeutic modality has demonstrated its great potential in cancer therapy.